Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

Michael R. McClung, Michael A. Bolognese, Farhad Sedarati, Robert R. Recker, Paul D. Miller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Monthly oral ibandronate has been shown to increase bone mineral density (BMD) and reduce bone turnover in postmenopausal women with osteoporosis, but its efficacy has not been investigated in women with low bone mass. The objective of this study was to examine the efficacy and safety of monthly oral ibandronate (150 mg) treatment in postmenopausal women with low bone mass. Methods: This 1-year, double-blind, placebo-controlled, randomized study enrolled ambulatory postmenopausal women aged 45-60 years with baseline lumbar spine (LS) BMD T-score <- 1.0 and > - 2.5 and baseline T-score > - 2.5 at the total hip, trochanter, and femoral neck (collectively defined as the proximal femur) and no prior vertebral or low-trauma osteoporotic fractures at baseline. Subjects received either 150 mg monthly oral ibandronate or placebo. All subjects received calcium and vitamin D supplements. The primary endpoint was the relative change from baseline (%) in mean LS BMD at 1 year (intent-to-treat population). Treatment groups were compared by means of a two-way ANOVA model which adjusted for independent factors including treatment group, baseline LS BMD T-score, and time since menopause. Responder analyses examined the percentage of participants with changes from baseline in LS BMD and proximal femur BMD ≥ 0%. Adverse events and safety laboratory parameters were monitored continuously. Results: A total of 77 women received monthly ibandronate and 83 women received placebo. Subjects treated with ibandronate achieved larger increases in LS BMD after 1 year compared with subjects receiving placebo (3.7% vs - 0.4% [difference of 4.1%, p <0.0001]). After 3 months, median serum C-terminal telopeptide of type I collagen levels were reduced by > 55% in the ibandronate group compared with ∼ 4% in the placebo group. At 1 year, 88.2% of the participants treated with ibandronate achieved increases in LS BMD ≥ 0% compared with 38.6% of subjects receiving placebo. Treatment regimens were well tolerated in both the ibandronate-treated and placebo groups. Conclusion: Monthly ibandronate therapy prevents bone loss in postmenopausal women with low bone mass.

Original languageEnglish
Pages (from-to)418-422
Number of pages5
JournalBone
Volume44
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Postmenopausal Osteoporosis
Bone Density
Safety
Placebos
Spine
Femur
Bone and Bones
Therapeutics
ibandronic acid
Osteoporotic Fractures
Bone Remodeling
Femur Neck
Menopause
Vitamin D
Osteoporosis
Hip
Analysis of Variance
Calcium

All Science Journal Classification (ASJC) codes

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. / McClung, Michael R.; Bolognese, Michael A.; Sedarati, Farhad; Recker, Robert R.; Miller, Paul D.

In: Bone, Vol. 44, No. 3, 03.2009, p. 418-422.

Research output: Contribution to journalArticle

McClung, Michael R. ; Bolognese, Michael A. ; Sedarati, Farhad ; Recker, Robert R. ; Miller, Paul D. / Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. In: Bone. 2009 ; Vol. 44, No. 3. pp. 418-422.
@article{cd71363c1e3d43aea75270e1dd48627f,
title = "Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss",
abstract = "Introduction: Monthly oral ibandronate has been shown to increase bone mineral density (BMD) and reduce bone turnover in postmenopausal women with osteoporosis, but its efficacy has not been investigated in women with low bone mass. The objective of this study was to examine the efficacy and safety of monthly oral ibandronate (150 mg) treatment in postmenopausal women with low bone mass. Methods: This 1-year, double-blind, placebo-controlled, randomized study enrolled ambulatory postmenopausal women aged 45-60 years with baseline lumbar spine (LS) BMD T-score <- 1.0 and > - 2.5 and baseline T-score > - 2.5 at the total hip, trochanter, and femoral neck (collectively defined as the proximal femur) and no prior vertebral or low-trauma osteoporotic fractures at baseline. Subjects received either 150 mg monthly oral ibandronate or placebo. All subjects received calcium and vitamin D supplements. The primary endpoint was the relative change from baseline ({\%}) in mean LS BMD at 1 year (intent-to-treat population). Treatment groups were compared by means of a two-way ANOVA model which adjusted for independent factors including treatment group, baseline LS BMD T-score, and time since menopause. Responder analyses examined the percentage of participants with changes from baseline in LS BMD and proximal femur BMD ≥ 0{\%}. Adverse events and safety laboratory parameters were monitored continuously. Results: A total of 77 women received monthly ibandronate and 83 women received placebo. Subjects treated with ibandronate achieved larger increases in LS BMD after 1 year compared with subjects receiving placebo (3.7{\%} vs - 0.4{\%} [difference of 4.1{\%}, p <0.0001]). After 3 months, median serum C-terminal telopeptide of type I collagen levels were reduced by > 55{\%} in the ibandronate group compared with ∼ 4{\%} in the placebo group. At 1 year, 88.2{\%} of the participants treated with ibandronate achieved increases in LS BMD ≥ 0{\%} compared with 38.6{\%} of subjects receiving placebo. Treatment regimens were well tolerated in both the ibandronate-treated and placebo groups. Conclusion: Monthly ibandronate therapy prevents bone loss in postmenopausal women with low bone mass.",
author = "McClung, {Michael R.} and Bolognese, {Michael A.} and Farhad Sedarati and Recker, {Robert R.} and Miller, {Paul D.}",
year = "2009",
month = "3",
doi = "10.1016/j.bone.2008.09.011",
language = "English",
volume = "44",
pages = "418--422",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

AU - McClung, Michael R.

AU - Bolognese, Michael A.

AU - Sedarati, Farhad

AU - Recker, Robert R.

AU - Miller, Paul D.

PY - 2009/3

Y1 - 2009/3

N2 - Introduction: Monthly oral ibandronate has been shown to increase bone mineral density (BMD) and reduce bone turnover in postmenopausal women with osteoporosis, but its efficacy has not been investigated in women with low bone mass. The objective of this study was to examine the efficacy and safety of monthly oral ibandronate (150 mg) treatment in postmenopausal women with low bone mass. Methods: This 1-year, double-blind, placebo-controlled, randomized study enrolled ambulatory postmenopausal women aged 45-60 years with baseline lumbar spine (LS) BMD T-score <- 1.0 and > - 2.5 and baseline T-score > - 2.5 at the total hip, trochanter, and femoral neck (collectively defined as the proximal femur) and no prior vertebral or low-trauma osteoporotic fractures at baseline. Subjects received either 150 mg monthly oral ibandronate or placebo. All subjects received calcium and vitamin D supplements. The primary endpoint was the relative change from baseline (%) in mean LS BMD at 1 year (intent-to-treat population). Treatment groups were compared by means of a two-way ANOVA model which adjusted for independent factors including treatment group, baseline LS BMD T-score, and time since menopause. Responder analyses examined the percentage of participants with changes from baseline in LS BMD and proximal femur BMD ≥ 0%. Adverse events and safety laboratory parameters were monitored continuously. Results: A total of 77 women received monthly ibandronate and 83 women received placebo. Subjects treated with ibandronate achieved larger increases in LS BMD after 1 year compared with subjects receiving placebo (3.7% vs - 0.4% [difference of 4.1%, p <0.0001]). After 3 months, median serum C-terminal telopeptide of type I collagen levels were reduced by > 55% in the ibandronate group compared with ∼ 4% in the placebo group. At 1 year, 88.2% of the participants treated with ibandronate achieved increases in LS BMD ≥ 0% compared with 38.6% of subjects receiving placebo. Treatment regimens were well tolerated in both the ibandronate-treated and placebo groups. Conclusion: Monthly ibandronate therapy prevents bone loss in postmenopausal women with low bone mass.

AB - Introduction: Monthly oral ibandronate has been shown to increase bone mineral density (BMD) and reduce bone turnover in postmenopausal women with osteoporosis, but its efficacy has not been investigated in women with low bone mass. The objective of this study was to examine the efficacy and safety of monthly oral ibandronate (150 mg) treatment in postmenopausal women with low bone mass. Methods: This 1-year, double-blind, placebo-controlled, randomized study enrolled ambulatory postmenopausal women aged 45-60 years with baseline lumbar spine (LS) BMD T-score <- 1.0 and > - 2.5 and baseline T-score > - 2.5 at the total hip, trochanter, and femoral neck (collectively defined as the proximal femur) and no prior vertebral or low-trauma osteoporotic fractures at baseline. Subjects received either 150 mg monthly oral ibandronate or placebo. All subjects received calcium and vitamin D supplements. The primary endpoint was the relative change from baseline (%) in mean LS BMD at 1 year (intent-to-treat population). Treatment groups were compared by means of a two-way ANOVA model which adjusted for independent factors including treatment group, baseline LS BMD T-score, and time since menopause. Responder analyses examined the percentage of participants with changes from baseline in LS BMD and proximal femur BMD ≥ 0%. Adverse events and safety laboratory parameters were monitored continuously. Results: A total of 77 women received monthly ibandronate and 83 women received placebo. Subjects treated with ibandronate achieved larger increases in LS BMD after 1 year compared with subjects receiving placebo (3.7% vs - 0.4% [difference of 4.1%, p <0.0001]). After 3 months, median serum C-terminal telopeptide of type I collagen levels were reduced by > 55% in the ibandronate group compared with ∼ 4% in the placebo group. At 1 year, 88.2% of the participants treated with ibandronate achieved increases in LS BMD ≥ 0% compared with 38.6% of subjects receiving placebo. Treatment regimens were well tolerated in both the ibandronate-treated and placebo groups. Conclusion: Monthly ibandronate therapy prevents bone loss in postmenopausal women with low bone mass.

UR - http://www.scopus.com/inward/record.url?scp=59649112092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649112092&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2008.09.011

DO - 10.1016/j.bone.2008.09.011

M3 - Article

VL - 44

SP - 418

EP - 422

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -